Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

Abroad (travel likely)RecruitingPHASE2

Conditions

Urothelial Carcinoma · Muscle-invasive Bladder Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
Contact: Study coordinator (Nataliya Mar, MD) · ucstudy@uci.edu · 877-827-8839

Study leads

Nataliya Mar, MD
Principal Investigator
Chao Family Comprehensive Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Sacituzumab Govitecan Plus EV in Metastatic UC

Urothelial Cancer · Metastatic Urothelial Carcinoma · Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter

Abroad (travel likely)RecruitingPHASE1, PHASE2

Boston, United States

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Small Cell Neuroendocrine Carcinoma of Bladder · Bladder Cancer · Urothelial Carcinoma Bladder

Abroad (travel likely)RecruitingPHASE2

Washington D.C., United States · Baltimore, United States

Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract

Urothelial Carcinoma · Cancer

Abroad (travel likely)RecruitingPHASE2

Paris, France · Marseille, France

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Solid Tumor, Adult · Bladder Cancer · Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE1

North Melbourne, Australia